BYC-103 is under clinical development by BRL Medicine and currently in Phase II for Beta Thalassaemia. According to GlobalData, Phase II drugs for Beta Thalassaemia have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BYC-103’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BYC-103 is under development for the treatment of beta thalassemia. The drug candidate comprises of autologous hematopoietic stem cells modified by using CRISPR/Cas9 gene editing technology that target gamma-globin protein. It is administered through intravenous route.
For a complete picture of BYC-103’s drug-specific PTSR and LoA scores, buy the report here.